Valvular & structural heart diseaseRandomised controlled trial
Glucocorticoids to reduce permanent pacemaker implantation after transcatheter aortic valve implantation (TAVI): the GLUCO-TAVI randomised trial
- Prospective Randomised Open-label Blinded Endpoint (PROBE) design
- pilot study
Authors' conclusion
Glucocorticoids in TAVI are feasible and safe. The observed numerical difference in PPI did not reach statistical significance. Large-scale trials are needed to confirm the results of this pilot study.
Study context
- Population
- Patients undergoing TAVITAVI patients randomised
- Participants
- One hundred patients
- Comparison
- Glucocorticoids vs standard care in patients undergoing TAVI
- Primary endpoint
- Incidence of PPI
- Follow-up
- 1 month
Primary result
As reported in the abstract
Relative risk
0.50
95% CI 0.16–1.55
P = 0.23
By group
intervention group vs control group
RR 0.50 (95% CI 0.16–1.55); P = 0.23
Secondary outcomes
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| PPI · 1 year · no significant difference | 0.67 (0.26–1.73) | P = 0.41 | |
| New LBBB · no significant difference | 1.12 (0.66–1.89) | P = 0.66 | |
| 0.20.5125Relative risk (log scale) |
Safety
Complications, mortality and adverse events
- Mortality
- 4% vs 12%; p=0.27
- Adverse events
- n=3
- The intervention was safe, without differences in complications
Original publication
Glucocorticoids to reduce permanent pacemaker implantation after TAVI: the GLUCO-TAVI randomised trial. EuroIntervention. Published 15 May 2026. doi:10.4244/eij-d-26-00032
Summarised from the published abstract; every number is checked against it